[线粒体:癌细胞中疗法耐药性的关键驱动因素]
Comptes rendus biologies
|August 22, 2024
概括
线粒体代谢对于急性髓性白血病的治疗反应和耐药性至关重要. 线粒激进的概念解释了细胞如何适应治疗诱导的压力,并启动疾病复发.
科学领域:
- 在瘤学瘤学.
- 细胞的新陈代谢
- 血液学 血液学 血液学
背景情况:
- 能量代谢显著影响血液恶性瘤治疗结果.
- 线粒体代谢是急性髓性白血病 (AML) 治疗反应和耐药性的关键因素.
研究的目的:
- 审查线粒体代谢在AML治疗中的作用.
- 介绍和描述AML中的线粒体化概念.
主要方法:
- 文献综述侧重于能量代谢和AML.
- 对癌症治疗中线粒体功能的现有研究进行分析.
- 综合有关线粒体和疾病复发的信息.
主要成果:
- 线粒体代谢是AML细胞对治疗的反应和抵抗方式的组成部分.
- 压力反应 - - 线粒体变化 (Mitohormesis) 涉及到治疗诱导的适应.
- 这种适应机制有助于AML复发的开始.
结论:
- 了解线粒体代谢和线粒体转化是改善AML治疗策略的关键.
- 准代谢途径可能为AML提供新的治疗途径.
- 对线粒激素的进一步研究可以阐明AML复发的机制.
关键词:
<i>米托荷尔梅斯</i> 是一个癌症 癌症 癌症 癌症leukémies aiguës myéloides 这种白血病经常发生线粒体是一种线粒体.在cométabolisme上进行代谢.治疗性电阻是一种疗法.更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.6K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Electron Transport Chain: Complex I and II
12.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
